One world, one hope: The cost of providing antiretroviral therapy to all nations

AIDS

Volumn 12, Issue 16, 1998, Pages 2203-2209

  Hogg, Robert S ^a,b   Weber, Amy E ^a   Craib, Kevin J P ^a   Anis, Aslam H ^a   O'Shaughnessy, Michael V ^a   Schechter, Martin T ^a   Montaner, Julio S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Africa; AIDS; America; Antiretroviral therapy; Asia; Cost; Europe; HIV; World

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA; AFRICA SOUTH OF THE SAHARA; ARTICLE; ASIA; CENTRAL AMERICA; DRUG COST; EUROPE; HEALTH CARE AVAILABILITY; HEALTH ECONOMICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NORTH AMERICA; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME--PREVENTION AND CONTROL; DISEASES; DRUGS--COST; EPIDEMICS; HIV INFECTIONS--PREVENTION AND CONTROL; RESEARCH REPORT; TREATMENT; VIRAL DISEASES; WORLD;

ADULT; ANTI-HIV AGENTS; CHILD; DIRECT SERVICE COSTS; DRUG COSTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; SENSITIVITY AND SPECIFICITY; WORLD HEALTH;

EID: 0032511928     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199816000-00016     Document Type: Article

References (27)

1. World Health Organization: The current global situation of the HIV/AIDS pandemic. Wkly Epidemiol Rec 1997, 48:359-360.
2. Murray HW, Squires KE, Weiss W, et al.: Stavudine in patients with AIDS and AIDS-related complex: ACTG 089. J Infect Dis 1995, 171 (suppl 2):S123-S130.
3. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimetre. N Engl J Med 1995, 333:1662-1669.
4. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
5. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med 1997, 337:725-733.
6. Vella S: Clinical experience with saquinavir. AIDS 1996, 9:21-25.
7. Myers M, Montaner JSG, for the INCAS Study Group: A randomised double-blind, comparative trial of the effects of zidovudine, didanosine, and nevirapine combinations in anti viral naive, AIDS-free, HIV-infected patients with CD4+ cell counts 200-600 μl. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB294].
8. Carpenter CJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996: recommendation of an international panel. JAMA 1996, 276:146-154.
9. Therapeutic Guidelines for the Treatment of HIV/AIDS and Related Conditions. Vancouver: BC Centre for Excellence in HIV/AIDS; 1995.
10. Hogg RS, O'Shaughnessy MV, Gataric N, et al.: Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997, 349:1294.
11. Hogg RS, Heath KV, Yip B, et al.: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
12. UNAIDS: Report on the Global HIV/AIDS Epidemic. December 1997. Geneva: UNAIDS; 1997.
13. WHO: The implications of antiretroviral treatments. Informal consultations. April 1997. Geneva: UNAIDS.
14. Hogg RS, Anis A, Weber AE, et al.: Triple-combination antiretroviral therapy in sub-Saharan Africa [letter]. Lancet 1997, 350:1406.
15. Montaner JSG, Hogg RS, Weber AE, et al.: The cost of triple-drug anti-HIV therapy for adults in the Americas. JAMA 1998, 279:1263-1264.
16. Hogg RS, Weber AE, Craib KJP, et al.: One world, one hope: the cost of making antiretroviral therapy available to all nations. XII World AIDS Conference. Geneva, June-July 1998 [abstract 42283].
17. Joint United Nations Programme on HIV/AIDS: Report on the Global HIV/AIDS Epidemic. June 1998. Geneva: UNAIDS/WHO; 1998.
18. World Bank: World Development Report 1997. The State in a Changing World. Selected World Development Indicators. Washington, DC: World Bank; 1997.
19. United Nations: World Population 1996. New York: United Nations, Department of Economic and Social Information and Policy Analysis, Population Division; 1996.
20. Pan American Health Organization: Health Conditions in the Americas. Washington, DC: Pan American Health Organization; 1994.
21. IMS/Agouron Pharmaceuticals, Inc.: Updates on infection and treatment. December 1997. Positively Aware 1998, May/June: 16.
22. Timaeus I: Impact of the HIV epidemic on mortality in sub-Saharan Africa: evidence from national surveys and censuses. AIDS 1998, 12 (suppl 1):S15-S27.
23. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
24. Mansergh G, Haddix AC, Steketee RW, et al.: Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting. JAMA 1996, 276:139-145.
25. UNAIDS: UNAIDS Launches Initiative to Help Bridge Gap in Access to HIV/AIDS-Related Drugs in Developing World. Geneva: UNAIDS; 1997.
26. Doyle R: Access to safe drinking water [news]. Sci Am 1997, 277:38.
27. Daly HE: Beyond Growth. The Economics of Sustainable Development. Boston: Beacon Press; 1996.